Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in CpcPH due to Left Ventricular Dysfunction
NCT02070991Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Combined Pre- And Postcapillary Pulmonary Hypertension (Cpc-PH) comparing Macitentan with Placebo (2 arms). Primary endpoint: Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class at 12 weeks. Started Jul 2014; status: completed.
02
Drugs
macitentan
03
Conditions
Combined Pre- And Postcapillary Pulmonary Hypertension (Cpc-PH)
Beyond the preview
Go deeper on NCT02070991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070991.